Scientists have engineered a portable biosensor capable of detecting varying levels of brain-derived neurotrophic factor (BDNF), a crucial protein implicated in a range of mental health disorders, including major depressive disorder, schizophrenia, and bipolar disorder. This flexible, budget-friendly device processes a saliva sample in under three minutes, establishing itself as a swift, economical, and non-intrusive diagnostic method.
The global prevalence of mental health disorders is staggering, with over a billion individuals affected, and anxiety and depression being among the most common conditions. The World Health Organization's reports indicate a significant increase in these disorders across all demographics and income levels. Brazil, for instance, has seen a 134% surge in work absences due to mental health issues between 2022 and 2024, predominantly from depression and anxiety. This highlights an urgent need for accessible and efficient diagnostic tools.
The biosensor, a collaborative effort between the University of São Paulo (USP) and Embrapa Instrumentação, utilizes a flexible strip embedded with electrodes. When integrated with a portable analyzer, this setup can evaluate drops of human saliva. The device quickly ascertains the concentration of BDNF, a protein essential for the growth and maintenance of neurons, as well as critical brain functions like learning and memory.
Published in ACS Polymers Au, the research demonstrates the biosensor's remarkable ability to accurately measure extremely low concentrations of BDNF, ranging from 10⁻²⁰ to 10⁻¹⁰ grams per milliliter. This wide detection range is clinically significant, as very low protein levels can signal the presence of neurological and psychiatric disorders. With an estimated production cost of just $2.19 per unit, the biosensor is not only highly sensitive but also exceptionally affordable, making it suitable for widespread adoption, especially in resource-limited settings. The next phase involves securing a patent for this innovative technology.
Lower BDNF levels are strongly associated with depression and cognitive decline. This new test provides a critical tool for clinicians to identify and monitor these conditions earlier. Conversely, an increase in BDNF levels can indicate a patient's positive response to treatment, enabling better-informed adjustments to therapeutic interventions. The current gold-standard techniques for BDNF analysis, such as ELISA and HPLC, are time-consuming, require larger sample volumes, and depend on specialized laboratory facilities. The new biosensor offers a significant improvement by providing rapid results with minimal resources.
Paulo Augusto Raymundo Pereira, a leading researcher from the São Carlos Institute of Physics (IFSC-USP) and corresponding author of the study, emphasizes the biosensor's role in the evolving landscape of personalized medicine. He notes that the device can be optimized to suit various patient profiles, aligning with the trend towards treatments increasingly tailored to individual needs. This development not only promises more efficient diagnostics but also supports a more personalized approach to mental health care.
